U.S. officials granted full approval to a closely watched Alzheimer's drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.
Alzheimer's drug Leqembi has full FDA approval in the U.S. now and that means Medicare will pay for it
Post a Comment